Use of Antihypertensive Drugs and Ischemic Stroke Severity - Is There a Role for Angiotensin-II?

PLoS One. 2016 Nov 15;11(11):e0166524. doi: 10.1371/journal.pone.0166524. eCollection 2016.

Abstract

Background: The increase in angiotensin II (Ang II) formation by selected antihypertensive drugs is said to exhibit neuroprotective properties, but this translation into improvement in clinical outcomes has been inconclusive. We undertook a study to investigate the relationship between types of antihypertensive drugs used prior to a stroke event and ischemic stroke severity. We hypothesized that use of antihypertensive drugs that increase Ang II formation (Ang II increasers) would reduce ischemic stroke severity when compared to antihypertensive drugs that suppress Ang II formation (Ang II suppressors).

Methods: From the Malaysian National Neurology Registry, we included hypertensive patients with first ischemic stroke who presented within 48 hours from ictus. Antihypertensive drugs were divided into Ang II increasers (angiotensin-I receptor blockers (ARBs), calcium channel blockers (CCBs) and diuretics) and Ang II suppressors (angiotensin-converting-enzyme inhibitors (ACEIs) and beta blockers). We evaluated stroke severity during admission with the National Institute of Health Stroke Scale (NIHSS). We performed a multivariable logistic regression with the score being dichotomized at 15. Scores of less than 15 were categorized as less severe stroke.

Results: A total of 710 patients were included. ACEIs was the most commonly prescribed antihypertensive drug in patients using Ang II suppressors (74%) and CCBs, in patients prescribed with Ang II increasers at 77%. There was no significant difference in the severity of ischemic stroke between patients who were using Ang II increasers in comparison to patients with Ang II suppressors (OR: 1.32, 95%CI: 0.83-2.10, p = 0.24).

Conclusion: In our study, we found that use of antihypertensive drugs that increase Ang II formation was not associated with less severe ischemic stroke as compared to use of antihypertensive drugs that suppress Ang II formation.

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Aged
  • Angiotensin II / agonists
  • Angiotensin II / metabolism*
  • Angiotensin Receptor Antagonists / therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Antihypertensive Agents / therapeutic use*
  • Brain Ischemia / drug therapy*
  • Brain Ischemia / physiopathology
  • Calcium Channel Blockers / therapeutic use
  • Cross-Sectional Studies
  • Diuretics / therapeutic use
  • Female
  • Humans
  • Hypertension / drug therapy*
  • Hypertension / physiopathology
  • Malaysia
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Registries*
  • Severity of Illness Index
  • Stroke / drug therapy*
  • Stroke / physiopathology

Substances

  • Adrenergic beta-Antagonists
  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents
  • Calcium Channel Blockers
  • Diuretics
  • Angiotensin II

Grants and funding

WYH is funded by Julius Center for Health Sciences and Primary Care under the Honors Track Programme. IV is funded by the Dutch Heart Foundation for project Facts and Figures. The Honors Track Committee and the Dutch Heart Foundation had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The registry is funded by Ministry of Health Malaysia (ID: NMRR 08-1631-3189). Ministry of Health Malaysia had no role in the study design, analysis and preparation of the manuscript.